ADI-212 / Adicet Bio - LARVOL DELTA

Fourth Quarter 2025 and Recent Operational Highlights (PharmiWeb) - "Adicet plans to submit a regulatory filing for ADI-212 for the treatment of mCRPC in the third quarter of 2026, with Phase 1 enrollment expected to begin in the fourth quarter of 2026, subject to regulatory clearance."

New P1 trial • Castration-Resistant Prostate Cancer

Regulatory filing on track for ADI-212 in mCRPC (Businesswire) - "Adicet plans to submit a regulatory filing for ADI-212 for the treatment of mCRPC in the first quarter of 2026. The Company expects to share initial clinical data from the ADI-212 program in the second half of 2026, subject to regulatory clearance to proceed with a clinical trial."

Clinical data • New trial • Castration-Resistant Prostate Cancer

Presented ADI-212 preclinical data at the 32nd annual Prostate Cancer Foundation Scientific Retreat (Businesswire) - "In October, Adicet presented preclinical data at the 32nd Annual Prostate Cancer Foundation Scientific Retreat supporting these design elements and functional enhancements in multiple models of disease."

Preclinical • Prostate Cancer

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference (Businesswire) - "Adicet Bio...announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023....Preclinical study shows Adicet’s allogeneic gamma delta T cell platform may be a promising approach for prostate cancer."

Preclinical • Prostate Cancer

Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Businesswire) - "ADI-925, a novel engineered chimeric adaptor (CAd) gamma delta T cell product candidate, is engineered to provide broad antitumor activity in multiple heme and solid malignancies; IND submission expected second half of 2023; Four differentiated chimeric antigen receptor (CAR) and CAd programs targeting several hematologic and solid malignancies featured at SITC; Company to unveil new details from pipeline during R&D webcast event Thursday, November 10, 2022 at 9:00 a.m. ET....Adicet Bio, Inc..announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 10-11, 2022."

IND • Pipeline update • Preclinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Businesswire) - "Adicet Bio, Inc...announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor